Anemoside B4 prevents acute ulcerative colitis through inhibiting of TLR4/NF-κB/MAPK signaling pathway

Huimiao Ma,Mengjing Zhou,Wenbin Duan,Lanying Chen,Lingling Wang,Peng Liu

DOI: https://doi.org/10.1016/j.intimp.2020.106794

IF: 5.714

2020-10-01

International Immunopharmacology

Abstract:<p>Anemoside B4 (B4) is a compound extracted from <em>Pulsatilla chinensis(P. chinensis)</em>. Pharmacological studies have proved that it has certain anti-inflammatory activity. Acute ulcerative colitis (ulcerative colitis) is a non-specific inflammatory disease whose pathogenesis is not completely known, and there is no effective drugs. The purpose of this study was to investigate the protective effect of B4 on ulcerative colitis and its mechanism. In this study, the C57BL/6 mice model of ulcerative colitis was established by DSS [3% (w/v)] and treated with intraperitoneal injection of B4 and oral administration of mesalazine, respectively. During the experiment, the clinical symptoms of the mice were scored by the disease activity index (DAI). Histopathological changes were observed by HE staining. In addition, the effect of LPS on Raw264.7 cells was also studied. In vivo studies showed that B4 could prevent DSS-induced colitis mice from losing weight, shortening colon length and improving pathological changes of colon tissues. B4 significantly reduced levels of inflammatory cytokines IL-1β, IL-6, and TNF-α in colon tissues. In vitro experiments, B4 was almost nontoxic to Raw264.7 cells and could protect the Raw264.7 cells induced by LPS. In terms of mechanism, B4 significantly inhibited the activation of the TLR4 signaling pathway induced by DSS and down-regulate the expression of key proteins in the TLR4/NF-κB/MAPK signaling pathway in Raw264.7 cells induced by LPS. These findings suggest that the inhibition of B4 on ulcerative colitis may be through the TLR4/NF-κB/MAPK pathway. Therefore, B4 may be used as a potential drug for the treatment of ulcerative colitis.</p>

pharmacology & pharmacy,immunology

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve This paper aims to investigate the role and mechanism of Anemoside B4 (B4) in the treatment of acute ulcerative colitis. Specifically: 1. **Research Background**: - Ulcerative colitis (UC) is a non-specific inflammatory disease with an unclear pathogenesis and currently lacks effective drug treatments. - Anemoside B4 is a compound extracted from Pulsatilla, and previous studies have shown that it has certain anti-inflammatory activities. 2. **Research Objectives**: - To explore the protective effects and mechanisms of B4 on ulcerative colitis. - To verify through in vivo and in vitro experiments whether B4 can alleviate the symptoms of ulcerative colitis and elucidate its possible mechanisms of action. 3. **Main Findings**: - B4 can inhibit DSS-induced colitis in mice, reduce weight loss, colon shortening, and histopathological changes. - B4 significantly reduces the levels of inflammatory cytokines (such as IL-1β, IL-6, and TNF-α) in colon tissues. - In vitro experiments showed that B4 is almost non-toxic to RAW264.7 cells and can protect LPS-induced RAW264.7 cells. - Mechanistically, B4 significantly inhibits DSS-induced activation of the TLR4 signaling pathway and downregulates the expression of key proteins in the TLR4/NF-κB/MAPK signaling pathway in LPS-induced RAW264.7 cells. In summary, this paper attempts to validate the efficacy and mechanism of B4 as a potential drug for the treatment of ulcerative colitis through in vivo and in vitro experiments.

Anemoside B4 prevents acute ulcerative colitis through inhibiting of TLR4/NF-κB/MAPK signaling pathway

Amelioration of Dextran Sulfate Sodium-Induced Experimental Ulcer Colitis in Mice by Bacillus licheniformis

Anemoside B4 ameliorates dextran sulfate sodium (DSS)-induced colitis through inhibiting NLRP3 inflammasome and modulating gut microbiota

Anemoside B4 protects against chronic relapsing colitis in mice by modulating inflammatory response, colonic transcriptome and the gut microbiota

Anemoside B4 ameliorates TNBS-induced colitis through S100A9/MAPK/NF-κB signaling pathway

Pulsatillae radix extract alleviates DSS-induced colitis via modulating gut microbiota and inflammatory signaling pathway in mice

Anemoside B4, a new pyruvate carboxylase inhibitor, alleviates colitis by reprogramming macrophage function

Anemoside B4 Protects against Acute Lung Injury by Attenuating Inflammation through Blocking NLRP3 Inflammasome Activation and TLR4 Dimerization

Banxia Xiexin Decoction Protects Against Dextran Sulfate Sodium-Induced Chronic Ulcerative Colitis in Mice.

Protective effects of 4‐geranyloxy‐2,6‐dihydroxybenzophenonel on DSS‐induced ulcerative colitis in mice via regulation of cAMP/PKA/CREB and NF‐κB signaling pathways

Discovery of a New Anti-Inflammatory Agent from Anemoside B4 Derivatives and Its Therapeutic Effect on Colitis by Targeting Pyruvate Carboxylase

Anemoside B4 protects against IgE-dependent allergic responses by suppressing the PLC/IP3 and JAK/STAT3 pathways

Timosaponin BⅡ reduces colonic inflammation and alleviates DSS-induced ulcerative colitis by inhibiting NLRP3

Anemoside B4 prevents chronic obstructive pulmonary disease through alleviating cigarette smoke-induced inflammatory response and airway epithelial hyperplasia

TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice.

Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis

[Effect of Shaoyao Tang on ulcerative colitis in rats via regulation of TLR4/NF-κB signal pathway]

Buddlejasaponin IVb Alleviates DSS-Induced Ulcerative Colitis through the Nrf2/GPX4 Pathway and Gut Microbiota Modulation

Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota

Anemoside B4 Inhibits Vascular Smooth Muscle Cell Proliferation, Migration, and Neointimal Hyperplasia